Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback